BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BHV-1400 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BHV-1400\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07054684-901@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:BHV-1400: Phase 1 readout est. (NCT07054684)
DESCRIPTION:BHV-1400\, phase 1\, Chronic Kidney Disease.\nStudy: Study of B
 HV-1400 in IgA Nephropathy\nEstimated primary completion: July 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/bhv-1400#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07054684
URL:https://assetmemo.bio/drug/bhv-1400#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07642050-901@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:BHV-1400: Phase 3 readout est. (NCT07642050)
DESCRIPTION:BHV-1400\, phase 3\, Chronic Kidney Disease.\nStudy: A Study to
  Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropath
 y\nEstimated primary completion: September 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/bhv-1400#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07642050
URL:https://assetmemo.bio/drug/bhv-1400#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
